Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose IL-2 in COVID-19 related ARDS
NCT04357444Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2020
- Primary completion
- Nov 2020
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute respiratory distress syndrome (ARDS) comparing ILT101 with Placebo Comparator (2 arms). Primary endpoint: PaO2/FiO2 ratio at 11 days. Started Oct 2020; status: completed.
02
Drugs
Inleusin
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04357444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04357444.